Literature DB >> 15880332

Bloodletting as a cure for dropsy: heart failure down the ages.

Hector O Ventura1, Mandeep R Mehra.   

Abstract

BACKGROUND: Dropsy was a term used to describe generalized swelling and was synonymous with heart failure. Its treatment options were scanty and were aimed to cause "emptying of the system" or to relieve fluid retention. These remedies were rudimentary, erratic in action, and associated with inconvenient side effects. METHODS AND
RESULTS: Bloodletting, either by venesection or by leeches, was a popular way to alleviate symptoms from dropsy. Although bloodletting, purgatives, cauterization, and Southey tubes were drastic, their use demonstrated that physicians were not powerless to help people with severe heart failure. Several centuries of intensive investigations in different areas of heart failure ended with the development of new therapeutic strategies that made bloodletting obsolete.
CONCLUSION: In an era when adequate treatment of heart failure has become a reality, it is appropriate to acknowledge those who paved the way to such great progress.

Entities:  

Mesh:

Year:  2005        PMID: 15880332     DOI: 10.1016/j.cardfail.2004.10.003

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  4 in total

1.  Peer reviewed publications in 2005.

Authors: 
Journal:  Ochsner J       Date:  2006

2.  J.A. Lindsay's Tonics and Tinctures for Cardiac Care (1889-1904).

Authors:  Tracy Freudenthaler
Journal:  Ulster Med J       Date:  2022-06-15

3.  Cardiovascular disease and global health equity: lessons from tuberculosis control then and now.

Authors:  Gene Bukhman; Alice Kidder
Journal:  Am J Public Health       Date:  2007-11-29       Impact factor: 9.308

4.  Belly fat or bloating? New insights into the physical appearance of St Anthony of Padua.

Authors:  Jessica Mongillo; Giulia Vescovo; Barbara Bramanti
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.